πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,257 results for β€œFirst” Clear

  1. Fosinopril

    The First People's Hospital of Lianyungang

    Chronic Kidney Disease

    approved small molecule active

    1 trial

  2. Glucagon-like peptide-1 receptor agonist：Semaglutide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    approved small molecule active

    1 trial

  3. Glycopyrronium in Combination With Tropisetron

    The First People's Hospital of Lianyungang

    Postoperative Nausea and Vomiting

    approved small molecule completed

    1 trial

  4. HALOPERIDOL, CLOZAPINE, TIAPRIDE, SERTINDOLE, PALIPERIDONE, OLANZAPINE, SULPIRIDE, ARIPIPRAZOLE, LURASIDONE, RISPERIDONE, AMISULPRIDE, CHLORPROMAZINE, PIMOZIDE, QUETIAPINE

    Disc Medicine

    HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose reduction/discontinuation.

    approved small molecule active

    1 trial

  5. Henagliflozin Proline Tablets treatment

    The First People's Hospital of Lianyungang

    Diabetes Type 2

    approved small molecule active

    1 trial

  6. High-dose anrikefon

    The First People's Hospital of Lianyungang

    Laparoscopic Surgery

    approved small molecule active

    2 trials

  7. Honghe Fujie lotion

    The First People's Hospital of Lianyungang

    Bacterial Vaginitis

    approved small molecule active

    1 trial

  8. Hydroxychloroquine Sulfate

    The First People's Hospital of Lianyungang

    Primary IgA Nephropathy

    approved small molecule completed

    1 trial

  9. Hydroxychloroquine Sulfate 200 Mg Tablet

    The First People's Hospital of Lianyungang

    Atrial Fibrillation

    approved small molecule active

    1 trial

  10. ICS/LABA

    The First People's Hospital of Lianyungang

    Asthma

    approved small molecule active

    1 trial

  11. IVC

    The First People's Hospital of Lianyungang

    Proliferative Diabetic Retinopathy

    approved small molecule active

    1 trial

  12. Icodextrin Peritoneal Dialysis Solution

    The First People's Hospital of Lianyungang

    Peritoneal Dialysis

    approved small molecule active

    1 trial

  13. Individual ATG

    The First People's Hospital of Lianyungang

    Hematopoietic Stem Cell Transplantation

    approved small molecule active

    1 trial

  14. Infliximab

    The First People's Hospital of Lianyungang

    Crohn's Diseases

    approved small molecule active

    1 trial

  15. Insulin

    The First People's Hospital of Lianyungang

    Brain Injuries

    approved small molecule active

    1 trial

  16. Insulin

    The First People's Hospital of Lianyungang

    Acute Pancreatitis

    approved small molecule active

    1 trial

  17. Intranasal dexmedetomidine-esketamine

    The First People's Hospital of Lianyungang

    Adenotonsillectomy

    approved small molecule active

    1 trial

  18. Intravenous Immunoglobulins, Human

    The First People's Hospital of Lianyungang

    Guillain-Barre Syndrome

    approved small molecule active

    1 trial

  19. Intravenous thrombolysis + edaravone

    The First People's Hospital of Lianyungang

    Ischemic Stroke

    approved small molecule active

    1 trial

  20. Irinotecan liposomes combined with cisplatin/carboplatin

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    approved small molecule active

    1 trial

  21. Ixazomib

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule completed

    1 trial

  22. JAK Inhibitor

    The First People's Hospital of Lianyungang

    Dermatomyositis, Adult Type

    approved small molecule active

    1 trial

  23. KANG FU PEN

    The First People's Hospital of Lianyungang

    Cervical Cancer

    approved small molecule active

    1 trial

  24. Keverprazan

    The First People's Hospital of Lianyungang

    H. Pylori Infection

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources